While pharmaceutical companies generally support patient-reported outcomes to support regulatory approvals, the industry seems to oppose their use in health care reimbursement, according to an Evaluate report.
Industry representatives during a meeting this week of the Medicare Evidence Development and Coverage Advisory Committee (Medcac) suggested the patient-reported data could become a condition of coverage, per the report.
Despite the industry’s opposition, the panel during its meeting backed four PROs:
- Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events;
- MD Anderson Symptom Inventory;
- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; and
- Patient-Reported Outcome Measurement Information System.
University of North Carolina’s Professor Ethan Basch was unsure why the pharmaceutical industry supported PROs for regulatory approvals but not reimbursement.
“I’m surprised at the reticence of some stakeholders to collect this data,” he said. “We are spending a lot of resources on this patient population, and to not collect patient-reported outcomes, which consists of handing somebody a questionnaire, seems absurd. This is minuscule.”